• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Apyx Medical Shares Dipped Over 60%; Here Are 123 Biggest Movers From Yesterday

    11/11/22 5:10:24 AM ET
    $AAPL
    $ABCL
    $ACVA
    $ADMA
    Computer Manufacturing
    Technology
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AAPL alert in real time by email

    Gainers

    • Fast Radius, Inc. (NASDAQ:FSRD) shares jumped 156.2% to close at $0.2608 on Thursday after dipping 40% on Wednesday. Fast Radius received Bankruptcy court approval of first day motions related to the company's voluntary Chapter 11 petitions filed on November 7.
    • SHF Holdings, Inc. (NASDAQ:SHFS) jumped 86.7% to close at $3.79 on Thursday.
    • EpicQuest Education Group International Limited (NASDAQ:EEIQ) rose 72.1% to close at $1.79.
    • Magnite, Inc. (NASDAQ:MGNI) shares surged 65.6% to close at $9.57 after the company reported better-than-expected Q3 results.
    • TG Therapeutics, Inc. (NASDAQ:TGTX) jumped 63.4% to close at $8.43 following narrower-than-expected Q3 loss.
    • Digital Turbine, Inc. (NASDAQ:APPS) shares climbed 60.9% to close at $17.33 after reporting upbeat Q2 earnings.
    • Cosmos Holdings Inc. (NASDAQ:COSM) gained 57.5% to settle at $0.1150.
    • Repay Holdings Corporation (NASDAQ:RPAY) climbed 50.7% to close at $6.60 after the company reported upbeat Q3 results.
    • BioLife Solutions, Inc. (NASDAQ:BLFS) surged 42.8% to close at $24.70 after reporting Q3 results.
    • Ebix, Inc. (NASDAQ:EBIX) jumped 42.1% to close at $22.78. Ebix reported third-quarter FY22 revenue growth of 35% year-on-year to $257.9 million.
    • Auddia Inc. (NASDAQ:AUUD) rose 41.5% to settle at $1.50. Auddia recently reported the departure of its Chief Financial Officer Brian Hoff.
    • WeTrade Group, Inc. (NASDAQ:WETG) surged 41% to close at $1.10.
    • Versus Systems Inc. (NASDAQ:VS) gained 40.9% to settle at $3.00.
    • Motorsport Games Inc. (NASDAQ:MSGM) gained 38.7% to close at $8.99. Motorsport Games announced completion of previously announced 1-for-10 reverse stock split.
    • Lantronix, Inc. (NASDAQ:LTRX) climbed 38.5% to close at $5.32 after the company posted upbeat Q1 earnings and raised FY23 forecast.
    • ShiftPixy, Inc. (NASDAQ:PIXY) gained 38.3% to settle at $12.21.
    • Invitae Corporation (NYSE:NVTA) rose 36.4% to close at $3.11 after the company reported better-than-expected Q3 results and reduced 2022 cash burn guidance.
    • PetIQ, Inc. (NASDAQ:PETQ) climbed 36.4% to close at $9.75 following Q3 results.
    • Rackspace Technology, Inc. (NYSE:RXT) climbed 35.8% to close at $5.92 following upbeat quarterly results.
    • Cardlytics, Inc. (NASDAQ:CDLX) gained 33.2% to close at $4.89.
    • Evolv Technologies Holdings, Inc. (NASDAQ:EVLV) rose 32.6% to close at $3.50 after the company reported better-than-expected Q3 results and raised its FY22 guidance.
    • Paymentus Holdings, Inc. (NYSE:PAY) climbed 32% to close at $11.68 after the company reported better-than-expected Q3 sales results.
    • Redfin Corporation (NASDAQ:RDFN) gained 31.8% to close at $4.31 following Q3 results.
    • Schmitt Industries, Inc. (NASDAQ:SMIT) gained 31.7% to close at $1.2250.
    • Carvana Co. (NYSE:CVNA) gained 31.6% to close at $9.99.
    • YETI Holdings, Inc. (NYSE:YETI) jumped 31.6% to close at $39.92 after the company reported better-than-expected Q3 EPS and sales results.
    • Compass, Inc. (NYSE:COMP) gained 31.4% to close at $2.43.
    • ZimVie Inc. (NASDAQ:ZIMV) climbed 31.3% to settle at $9.64 following strong quarterly earnings.
    • Consumer Portfolio Services, Inc. (NASDAQ:CPSS) climbed 31.2% to close at $8.67 following Q3 results.
    • Purple Innovation, Inc. (NASDAQ:PRPL) climbed 31.1% to close at $4.47 after the company reported better-than-expected Q3 results and raised its FY22 adjusted EBITDA guidance.
    • Fair Isaac Corporation (NYSE:FICO) jumped 31.1% to settle at $581.78 after the company reported better-than-expected Q4 EPS and sales results.
    • IGM Biosciences, Inc. (NASDAQ:IGMS) gained 30.4% to close at $20.93.
    • RingCentral, Inc. (NYSE:RNG) climbed 30.1% to close at $36.90 after the company reported better-than-expected Q3 EPS and sales results.
    • 2U, Inc. (NASDAQ:TWOU) gained 29.8% to close at $8.76. 2U recently reported better-than-expected Q3 sales results.
    • Surgery Partners, Inc. (NASDAQ:SGRY) climbed 29.6% to close at $28.89. Surgery Partners recently posted Q3 adjusted EPS of $(0.02).
    • Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) rose 29.6% to close at $8.36. Theseus Pharmaceuticals Director Carl Gordon bought a total of 192,000 shares at an average price of $5.21.
    • Unity Software Inc. (NYSE:U) gained 29.4% to close at $27.82 after the company reported better-than-expected Q3 sales results and issued Q4 and FY22 sales guidance above estimates.
    • BioXcel Therapeutics, Inc. (NASDAQ:BTAI) rose 29.3% to close at $14.75 following Q3 results.
    • Stitch Fix, Inc. (NASDAQ:SFIX) climbed 28.3% to settle at $4.17.
    • Wayfair Inc. (NYSE:W) climbed 28% to close at $36.80.
    • ADMA Biologics, Inc. (NASDAQ:ADMA) jumped 27.5% to settle at $3.15 after the company reported better-than-expected Q3 results and raised FY22 guidance.
    • Sunrun Inc. (NASDAQ:RUN) gained 27.4% to close at $30.79.
    • Upstart Holdings, Inc. (NASDAQ:UPST) rose 27.2% to close at $21.70.
    • Cryoport, Inc. (NASDAQ:CYRX) gained 27% to settle at $20.11. CryoPort recently reported worse-than-expected Q3 EPS and sales results.
    • Vericel Corporation (NASDAQ:VCEL) jumped 27% to close at $22.41. Vericel reported worse-than-expected Q3 EPS and sales results and lowered FY22 sales guidance.
    • Opendoor Technologies Inc. (NASDAQ:OPEN) gained 26.5% to settle at $1.91.
    • RAPT Therapeutics, Inc. (NASDAQ:RAPT) rose 26.2% to close at $21.98. RAPT Therapeutics posted a Q3 loss of $0.63 per share.
    • GitLab Inc. (NASDAQ:GTLB) gained 25.6% to settle at $42.99.
    • 908 Devices Inc. (NASDAQ:MASS) climbed 25.2% to close at $15.01.
    • Adaptive Biotechnologies Corporation (NASDAQ:ADPT) rose 25% to close at $9.06.
    • Coupa Software Incorporated (NASDAQ:COUP) gained 24.9% to close at $52.66.
    • Cloudflare, Inc. (NYSE:NET) rose 24.9% to close at $47.27.
    • ACV Auctions Inc. (NASDAQ:ACVA) jumped 24.8% to settle at $8.31 after the company reported better-than-expected Q3 EPS and sales results.
    • 10x Genomics, Inc. (NASDAQ:TXG) rose 24.4% to close at $37.82.
    • Fossil Group, Inc. (NASDAQ:FOSL) gained 24.1% to close at $4.18 after the company reported better-than-expected Q3 sales results.
    • Quanterix Corporation (NASDAQ:QTRX) jumped 24% to close at $11.72.
    • PAR Technology Corporation (NYSE:PAR) rose 24% to settle at $25.27.
    • Atara Biotherapeutics, Inc. (NASDAQ:ATRA) gained 24% to close at $4.81. Atara Biosciences recently reported worse-than-expected Q3 results.
    • Affirm Holdings, Inc. (NASDAQ:AFRM) jumped 23.9% to close at $14.99.
    • The E.W. Scripps Company (NASDAQ:SSP) jumped 23.1% to close at $12.79.
    • GoodRx Holdings, Inc. (NASDAQ:GDRX) rose 22.9% to close at $4.99. GoodRx said through unit, the company entered into agreement for sale of the company’s backend virtual care technology to Wheel Health for $19.5 million in cash.
    • Fisker Inc. (NYSE:FSR) jumped 22.9% to close at $8.00.
    • VIZIO Holding Corp. (NYSE:VZIO) gained 22.8% to close at $11.31 following Q3 results.
    • Coupang, Inc.. (NYSE:CPNG) rose 22.6% to close at $19.97 after the company reported better-than-expected Q3 EPS results.
    • Kornit Digital Ltd. (NASDAQ:KRNT) gained 22.6% to close at $28.33. Kornit Digital recently posted Q3 adjusted EPS of $(0.21).
    • Dutch Bros Inc. (NYSE:BROS) jumped 22.4% to settle at $35.72 after the company reported better-than-expected Q3 EPS and sales results and issued FY22 revenue guidance above analyst estimates.
    • Revolve Group, Inc. (NYSE:RVLV) rose 21.9% to close at $24.66.
    • Montrose Environmental Group, Inc. (NYSE:MEG) gained 21.4% to close at $46.00.
    • Precigen, Inc. (NASDAQ:PGEN) gained 21.1% to close at $1.78 following strong Q3 results.
    • Veracyte, Inc. (NASDAQ:VCYT) rose 21.1% to settle at $27.96. Veracyte recently reported better-than-expected Q3 EPS and sales results.
    • Sterling Check Corp. (NASDAQ:STER) jumped 21.1% to close at $14.85. Sterling Check recently reported worse-than-expected Q3 adjusted EPS results and lowered FY22 sales guidance.
    • Beyond Meat, Inc. (NASDAQ:BYND) gained 20.1% to close at $14.20 after the company reported Q3 earnings results.
    • Limbach Holdings, Inc. (NASDAQ:LMB) jumped 19.9% to close at $9.11 following upbeat quarterly earnings.
    • The Trade Desk, Inc. (NASDAQ:TTD) gained 19.1% to close at $47.51. The Trade Desk reported better-than-expected Q3 EPS and sales results.
    • CarParts.com, Inc. (NASDAQ:PRTS) jumped 17.9% to close at $4.75 after the company reported better-than-expected Q3 EPS results.
    • Block, Inc. (NYSE:SQ) climbed 17.8% to close at $67.40.
    • Rivian Automotive, Inc. (NASDAQ:RIVN) gained 17.4% to close at $32.96 after the company reported better-than-expected Q3 EPS results.
    • Lightwave Logic, Inc. (NASDAQ:LWLG) surged 16.4% to close at $8.18 after the company issued Q3 2022 corporate update.
    • Olo Inc. (NYSE:OLO) jumped 16.4% to close at $8.68 after posting strong quarterly results.
    • N-able, Inc. (NYSE:NABL) gained 16.3% to close at $11.27 following Q3 results.
    • Warby Parker Inc. (NYSE:WRBY) gained 14.9% to close at $15.20 following strong quarterly sales.
    • Marqeta, Inc. (NASDAQ:MQ) rose 14.9% to close at $7.17 after the company reported better-than-expected Q3 sales results.
    • Amazon.com, Inc. (NASDAQ:AMZN) climbed 12.2% to settle at $96.63 as stocks gained following softer-than-expected October inflation figures.
    • AST SpaceMobile, Inc. (NASDAQ:ASTS) rose 12.2% to close at $7.44 after declining around 9% on Wednesday.
    • Trip.com Group Limited (NASDAQ:TCOM) jumped 10% to close at $27.50 after dropping 8% on Wednesday.
    • CleanSpark, Inc. (NASDAQ:CLSK) rose 9.5% to close at $2.72 after dropping 15% on Wednesday.
    • AbCellera Biologics Inc. (NASDAQ:ABCL) rose 9.3% to close at $12.91 after the company reported better-than-expected Q3 results.
    • Apple Inc. (NASDAQ:AAPL) jumped 8.9% to close at $146.87. Apple hired a startup founder and former Meta Platforms Facebook executive to run its information systems group after departures in that department, Bloomberg reported.
    • Microsoft Corporation (NASDAQ:MSFT) rose 8.2% to close at $242.98.
    • Tesla, Inc. (NASDAQ:TSLA) rose 7.4% to settle at $190.72. The stock traded higher in sympathy with major indices are higher following key U.S. economic data, which showed a slowdown in inflation and a rise in jobless claims. This has alleviated some concerns of high inflation and a tight labor market.
    • Heliogen, Inc. (NYSE:HLGN) shares gained 7% to close at $1.07 after dipping 25% on Wednesday. Heliogen recently posted a Q3 loss of $0.14 per share.

     

     


    Losers

    • Apyx Medical Corporation (NASDAQ:APYX) shares tumbled 60.5% to close at $1.74 on Thursday after the company reported downbeat Q3 earnings and updated FY22 guidance.
    • Veru Inc. (NASDAQ:VERU) fell 53.6% to close at $6.97 on Thursday after the company reported that FDA’s Pulmonary-Allergy Drugs Advisory Committee voted 8-5 that the “known and potential benefits” of its sabizabulin in treating adult hospitalized COVID-19 patients at high risk of acute respiratory distress syndrome do not outweigh the “known and potential risks.”
    • AGBA Acquisition Limited (NASDAQ:AGBA) fell 50.9% to close at $5.50. AGBA Acquisition announced approval of business combination and ability of stockholders to withdraw ordinary shares tendered for redemption.
    • VIQ Solutions Inc. (NASDAQ:VQS) dropped 50.8% to settle at $0.3050. VIQ Solutions posted a Q3 loss of $0.04 per share.
    • Vacasa, Inc. (NASDAQ:VCSA) dropped 45% to close at $1.97 after the company reported worse-than-expected Q3 EPS results.
    • 8i Acquisition 2 Corp. (NASDAQ:LAX) fell 42.7% to close at $5.51.
    • Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) fell 42.2% to close at $1.67. BrainStorm Cell Therapeutics received refusal to file letter from the FDA for its new biologics license application for NurOwn for the treatment of ALS.
    • Grom Social Enterprises, Inc. (NASDAQ:GROM) fell 41.4% to close at $0.1612.
    • Jounce Therapeutics, Inc. (NASDAQ:JNCE) fell 41.2% to close at $1.17. Jounce Therapeutics posted a Q3 loss of $0.60 per share.
    • Edgio, Inc. (NASDAQ:EGIO) dropped 35.7% to close at $1.39 after the company reported worse-than-expected Q3 sales results and issued Q4 sales guidance below analyst estimates.
    • Cano Health, Inc. (NYSE:CANO) shares declined 34.7% to close at $2.18 after the company reported worse-than-expected Q3 EPS and sales results. Raymond James downgraded Cano Health from Outperform to Market Perform.
    • EQRx, Inc. (NASDAQ:EQRX) dipped 28.6% to close at $3.89 following Q3 earnings.
    • Mercurity Fintech Holding Inc. (NASDAQ:MFH) fell 26.1% to settle at $0.5250.
    • Monopar Therapeutics Inc. (NASDAQ:MNPR) dropped 24.8% to close at $3.30. Monopar Therapeutics posted a Q3 loss of $0.19 per share.
    • Vigil Neuroscience, Inc. (NASDAQ:VIGL) fell 23.8% to settle at $9.38. Vigil Neuroscience posted a Q3 loss of $0.53 per share.
    • Conformis, Inc. (NASDAQ:CFMS) dipped 23.4% to close at $1.42. Conformis recently effected a 1-for-25 reverse stock split.
    • BioLineRx Ltd. (NASDAQ:BLRX) declined 22.3% to settle at $0.60. BioLineRx announced US FDA acceptance of new drug application for APHEXDA in stem cell mobilization.
    • Rockley Photonics Holdings Limited (NASDAQ:RKLY) dropped 21.7% to close at $0.29 after the company reported worse-than-expected Q3 sales results and issued 2022 revenue guidance below estimates.
    • Azul S.A. (NYSE:AZUL) declined 20.4% to settle at $7.01. Azul posted a Q3 loss of $0.72 per share.
    • Advantage Solutions Inc. (NASDAQ:ADV) fell 20% to close at $2.60 following weak quarterly sales.
    • Minim, Inc. (NASDAQ:MINM) fell 19.2% to close at $0.1802 following downbeat Q3 results.
    • Trevena, Inc. (NASDAQ:TRVN) fell 19.1% to close at $2.47. Trevena posted a Q3 loss of $0.09 per share.
    • NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) fell 18.5% to close at $1.32 after jumping around 30% on Wednesday.
    • FGI Industries Ltd. (NASDAQ:FGI) fell 17.9% to close at $2.52 after the company posted downbeat Q3 results and lowered FY22 forecast.
    • SunOpta Inc. (NASDAQ:STKL) declined 16% to settle at $8.77 following Q3 results.
    • Payoneer Global Inc. (NASDAQ:PAYO) dropped 15.4% to close at $5.76 following Q3 results.
    • Organogenesis Holdings Inc. (NASDAQ:ORGO) shares fell 14.9% to close at $2.63 after the company reported worse-than-expected Q3 EPS and sales results. The company also issued FY22 sales guidance below analyst estimates.
    • Xometry, Inc. (NASDAQ:XMTR) dropped 14.5% to close at $43.12 after the company issued weak sales forecast.
    • Gol Linhas Aéreas Inteligentes S.A. (NYSE:GOL) declined 13.7% to settle at $3.02.
    • Desktop Metal, Inc. (NYSE:DM) fell 11.9% to close at $1.93 after the company reported worse-than-expected Q3 results.
    • TechTarget, Inc. (NASDAQ:TTGT) declined 10% to close at $45.60 after the company reported worse-than-expected Q3 sales results. The company also issued Q4 and FY22 sales guidance below analyst estimates.
    • Montauk Renewables, Inc. (NASDAQ:MNTK) dropped 8.7% to close at $11.77 following downbeat Q3 results.
    Get the next $AAPL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AAPL
    $ABCL
    $ACVA
    $ADMA

    CompanyDatePrice TargetRatingAnalyst
    Wayfair Inc.
    $W
    2/20/2026$114.00 → $105.00Overweight
    Analyst
    Affirm Holdings Inc.
    $AFRM
    2/20/2026$55.00Neutral
    Robert W. Baird
    YETI Holdings Inc.
    $YETI
    2/20/2026$54.00Neutral → Buy
    B. Riley Securities
    Paymentus Holdings Inc.
    $PAY
    2/20/2026$35.00Outperform → Strong Buy
    Raymond James
    N-able Inc.
    $NABL
    2/20/2026$9.50 → $5.50Market Perform
    BMO Capital Markets
    Fossil Group Inc.
    $FOSL
    2/19/2026$7.00Outperform
    Northland Capital
    Upstart Holdings Inc.
    $UPST
    2/17/2026$30.00Sell → Neutral
    Compass Point
    YETI Holdings Inc.
    $YETI
    2/17/2026$60.00Neutral → Buy
    Roth Capital
    More analyst ratings

    $AAPL
    $ABCL
    $ACVA
    $ADMA
    SEC Filings

    View All

    Atara Biotherapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events

    8-K - Atara Biotherapeutics, Inc. (0001604464) (Filer)

    2/23/26 8:29:11 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AST SpaceMobile Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Other Events, Unregistered Sales of Equity Securities, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - AST SpaceMobile, Inc. (0001780312) (Filer)

    2/20/26 5:13:56 PM ET
    $ASTS
    Telecommunications Equipment
    Consumer Discretionary

    Advantage Solutions Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Advantage Solutions Inc. (0001776661) (Filer)

    2/20/26 4:50:02 PM ET
    $ADV
    Real Estate

    $AAPL
    $ABCL
    $ACVA
    $ADMA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Analyst reiterated coverage on Wayfair with a new price target

    Analyst reiterated coverage of Wayfair with a rating of Overweight and set a new price target of $105.00 from $114.00 previously

    2/20/26 10:42:01 AM ET
    $W
    Catalog/Specialty Distribution
    Consumer Discretionary

    Robert W. Baird initiated coverage on Affirm with a new price target

    Robert W. Baird initiated coverage of Affirm with a rating of Neutral and set a new price target of $55.00

    2/20/26 8:23:24 AM ET
    $AFRM
    Finance: Consumer Services
    Finance

    YETI Holdings upgraded by B. Riley Securities with a new price target

    B. Riley Securities upgraded YETI Holdings from Neutral to Buy and set a new price target of $54.00

    2/20/26 8:21:13 AM ET
    $YETI
    Recreational Games/Products/Toys
    Consumer Discretionary

    $AAPL
    $ABCL
    $ACVA
    $ADMA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    March 11, 2025 - FDA Roundup: March 11, 2025

    For Immediate Release: March 11, 2025 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:Today, the FDA published a General Correspondence Letter issued to Mid-Link Technology Testing Co., Ltd. The FDA is vigilant in ensuring data submitted to the FDA can be relied upon to assess the effectiveness, safety, or risk of a device. The FDA has noted an incr

    3/13/25 3:14:00 PM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    FDA Approval for BRIUMVI issued to TG THERAPEUTICS, INC

    Submission status for TG THERAPEUTICS, INC's drug BRIUMVI (SUPPL-11) with active ingredient UBLITUXIMAB-XIIY has changed to 'Approval' on 10/30/2024. Application Category: BLA, Application Number: 761238, Application Classification:

    10/31/24 4:38:40 AM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    September 17, 2024 - FDA Roundup: September 17, 2024

    For Immediate Release: September 17, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a draft guidance, “Integrating Randomized Controlled Trials for Drug and Biological Products into Routine Clinical Practice,” which, when finalized, will support the conduct of randomized controlled trials with streamlined protocols a

    9/17/24 2:34:22 PM ET
    $AAPL
    Computer Manufacturing
    Technology

    $AAPL
    $ABCL
    $ACVA
    $ADMA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Admin. and Legal Officer Freedman Lori was granted 245,905 shares and covered exercise/tax liability with 14,267 shares, increasing direct ownership by 29% to 1,023,355 units (SEC Form 4)

    4 - Organogenesis Holdings Inc. (0001661181) (Issuer)

    2/20/26 5:29:07 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vice President, Strategy Cavorsi Robert was granted 110,040 shares and covered exercise/tax liability with 5,432 shares, increasing direct ownership by 61% to 276,115 units (SEC Form 4)

    4 - Organogenesis Holdings Inc. (0001661181) (Issuer)

    2/20/26 5:28:53 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Commercial Officer Grow Brian was granted 282,705 shares and covered exercise/tax liability with 11,768 shares, increasing direct ownership by 43% to 899,355 units (SEC Form 4)

    4 - Organogenesis Holdings Inc. (0001661181) (Issuer)

    2/20/26 5:28:21 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AAPL
    $ABCL
    $ACVA
    $ADMA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Stanton John W bought $1,986,750 worth of shares (5,000 units at $397.35), increasing direct ownership by 6% to 83,905 units (SEC Form 4)

    4 - MICROSOFT CORP (0000789019) (Issuer)

    2/18/26 6:14:22 PM ET
    $MSFT
    Computer Software: Prepackaged Software
    Technology

    Chief Executive Officer Siokas Grigorios bought $145,000 worth of shares (388,532 units at $0.37), increasing direct ownership by 5% to 8,861,914 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    2/13/26 10:05:37 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Chief Executive Officer Siokas Grigorios bought $120,000 worth of shares (291,262 units at $0.41), increasing direct ownership by 4% to 8,473,382 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    2/12/26 2:20:08 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $AAPL
    $ABCL
    $ACVA
    $ADMA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Atara Biotherapeutics Provides a Business Update

    Atara renegotiates one-time milestone payment with HCRx Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that the Company entered into an amendment (the Amendment) to the Purchase and Sale Agreement dated as of December 20, 2022 with a fund managed by HealthCare Royalty ("HCRx"). Under the terms of the Amendment, HCRx agreed to amend the due date of the one-time of $9.0 million cash payment associated with the achievement of a certain milestone within the Amended and Restated Commercializa

    2/23/26 8:00:00 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update

    NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held, Thursday, February 26, 2026, at 8:30 AM ET to discuss results for the fourth quarter and full year 2025 and to provide a business outlook for 2026. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Earnings Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com.

    2/23/26 7:30:00 AM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Omdia: Apple and HONOR Claim Record Market Shares as Europe's Smartphone Shipment Dips 1% in 2025

    The latest research from Omdia reveals that the European smartphone market declined by 1% in 2025 to 134.2 million units, marking the end of a disruptive year defined by subdued demand and new regulations requiring eco-design and USB-C. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223432918/en/Europe (excluding Russia) smartphone market shipment, 2014 to 2025 Samsung remained Europe's largest smartphone vendor, with shipments marginally growing to 46.6 million units. After a slow 1H25 caused by the absence of the Galaxy A0x series, Samsung bounced back in 2H25, particularly by leveraging a discounted version of the Galaxy A

    2/23/26 6:48:00 AM ET
    $TTGT
    Telecommunications Equipment
    Telecommunications

    $AAPL
    $ABCL
    $ACVA
    $ADMA
    Leadership Updates

    Live Leadership Updates

    View All

    YETI Announces CFO Transition

    AUSTIN, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) -- YETI Holdings, Inc. ("YETI") (NYSE:YETI) today announced that Scott Bomar has been appointed Senior Vice President, Chief Financial Officer and Treasurer, effective February 23, 2026 (the "Effective Date"). Mr. Bomar succeeds Mike McMullen, who will cease to serve as YETI's Chief Financial Officer as of the Effective Date. Mr. McMullen will serve in an advisory capacity from the Effective Date until May 31, 2026 to facilitate a smooth transition. Mr. Bomar joins YETI from The Home Depot, Inc. ("Home Depot"), where he served in positions of increasing responsibility over nearly two decades, most recently serving as Senior Vice President of F

    2/19/26 6:00:00 AM ET
    $YETI
    Recreational Games/Products/Toys
    Consumer Discretionary

    Scripps appoints VP, network sports and client partnerships to connect advertisers with sports portfolio

    CINCINNATI, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The E.W. Scripps Company (NASDAQ:SSP) has named Oliver Gray vice president, network sports and client partnerships, effective immediately, adding a proven sports sponsorship and advertising leader to fuel growth across its expanding sports and entertainment platforms. Gray will lead efforts to connect national advertisers with Scripps' platforms – including its rapidly growing sports portfolio – and will work closely across Scripps' network sales and Scripps Sports teams to develop integrated brand partnerships that deepen client relationships and drive revenue. He reports to Brian Norris, Scripps executive vice president and chief revenue o

    2/18/26 11:00:00 AM ET
    $SSP
    Broadcasting
    Industrials

    Sunbit Appoints Shachar G. Scott as Chief Marketing Officer to Accelerate its Next Phase of Growth

    Veteran global marketing leader joins from Meta as Sunbit scales products, partnerships and infrastructure to serve millions more consumers Sunbit, the personalized financial partner for everyday life, today announced the appointment of Shachar G. Scott as Chief Marketing Officer, signaling a pivotal next chapter in the company's growth. Scott brings more than 25 years of experience building and scaling global brands across technology and consumer products with leadership roles at Meta (NASDAQ:META), Apple (NASDAQ:AAPL), Bumble (NASDAQ:BMBL) and Snap (NYSE:SNAP). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260212757677/en/S

    2/12/26 10:14:00 AM ET
    $AAPL
    $BMBL
    $META
    Computer Manufacturing
    Technology
    Computer Software: Programming Data Processing

    $AAPL
    $ABCL
    $ACVA
    $ADMA
    Financials

    Live finance-specific insights

    View All

    TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update

    NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held, Thursday, February 26, 2026, at 8:30 AM ET to discuss results for the fourth quarter and full year 2025 and to provide a business outlook for 2026. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Earnings Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com.

    2/23/26 7:30:00 AM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Quanterix To Report Fourth Quarter and Full Year 2025 Financial Results on March 2, 2026

    Quanterix Corporation (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that it will host a conference call on Monday, March 2, 2026, at 4:30 p.m. E.T., to discuss its fourth quarter and full year 2025 financial results. Quanterix will issue a press release regarding its fourth quarter and full year 2025 financial results prior to the conference call on Monday, March 2, 2026, after the market closes. The press release will be posted on the Quanterix website at http://www.quanterix.com/. To listen to the live conference call, investors can dial (800) 715-9871 or (646) 307-1963 and enter conference ID 79

    2/20/26 8:33:00 AM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    AST SpaceMobile to Provide Quarterly Business Update on March 2, 2026

    AST SpaceMobile, Inc. ("AST SpaceMobile") (NASDAQ:ASTS), the company building the first and only space-based cellular broadband network accessible directly by everyday smartphones, designed for both commercial and government applications, today announced it will hold a quarterly business update conference call on Monday, March 2nd at 5:00 p.m. (Eastern Time). AST SpaceMobile will be accepting questions from retail and institutional shareholders and management will answer select questions relating to AST SpaceMobile's business and financial results on the conference call. Investors are encouraged to submit questions to [email protected] and will also be added to our Investor Relati

    2/19/26 5:06:00 PM ET
    $ASTS
    Telecommunications Equipment
    Consumer Discretionary

    $AAPL
    $ABCL
    $ACVA
    $ADMA
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    What Does the Recent Purchase at Monopar Therapeutics Inc. on Jun 21 Indicate?

    Monopar Therapeutics Inc. has recently seen notable insider activity, with Chief Operating Officer Cittadine Andrew purchasing $25,574 worth of shares on June 21st, 2024. This purchase, comprising 32,508 units at $0.79, increased Cittadine's direct ownership by 21% to 186,132 units as reported in the SEC Form 4. When analyzing this transaction alongside other recent insider activities within the company, interesting patterns and trends start to emerge. Looking back, Cittadine Andrew has been consistently adding to his position in Monopar Therapeutics Inc. over the past few months, showcasing a strong conviction in the company's future prospects. On May 31st, Cittadine Andrew made a substan

    6/22/24 8:00:00 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AAPL
    $ABCL
    $ACVA
    $ADMA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Monopar Therapeutics Inc.

    SC 13D/A - Monopar Therapeutics (0001645469) (Subject)

    12/17/24 5:01:42 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Montrose Environmental Group Inc.

    SC 13G - Montrose Environmental Group, Inc. (0001643615) (Subject)

    12/17/24 4:20:32 PM ET
    $MEG
    Professional Services
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by Carvana Co.

    SC 13D/A - CARVANA CO. (0001690820) (Subject)

    12/16/24 6:13:26 PM ET
    $CVNA
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary